• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.替莫瑞林对伴有和不伴有颈背脂肪的HIV感染者的影响：III期双盲安慰剂对照试验的事后分析
J Clin Transl Sci. 2022 Dec 7;7(1):e40. doi: 10.1017/cts.2022.515. eCollection 2023.
2
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.泰莫瑞林（TH9507），一种生长激素释放因子类似物，对人类免疫缺陷病毒感染合并腹部肥胖患者的影响：两项多中心、双盲、安慰剂对照 3 期临床试验的汇总分析，包括安全性扩展数据。
J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16.
3
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.促胃液素释放肽，一种生长激素释放因子，对 HIV 感染合并腹部脂肪堆积患者的影响：一项随机安慰剂对照试验及安全性扩展研究。
J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff.
4
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.接受特立帕肽治疗的 HIV 感染患者内脏脂肪减少与代谢特征改善相关。
Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10.
5
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.感染HIV且腹部脂肪过多患者对生长激素释放因子类似物替莫瑞林治疗反应的预测因素
PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. eCollection 2015.
6
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.特立帕肽可减少内脏脂肪，改善 HIV 患者的肝酶水平。
AIDS. 2017 Oct 23;31(16):2253-2259. doi: 10.1097/QAD.0000000000001614.
7
Tesamorelin improves fat quality independent of changes in fat quantity.特马瑞林可改善脂肪质量，而不依赖于脂肪量的变化。
AIDS. 2021 Jul 15;35(9):1395-1402. doi: 10.1097/QAD.0000000000002897.
8
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.特索瑞林对伴有腹型肥胖的 HIV 患者炎症标志物的影响：与内脏脂肪减少的关系。
AIDS. 2011 Jun 19;25(10):1281-8. doi: 10.1097/QAD.0b013e328347f3f1.
9
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.特索美仑：在治疗 HIV 相关脂肪营养不良中的应用评价。
Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000.
10
Spotlight on tesamorelin in HIV-associated lipodystrophy.聚焦 tesamorelin 在 HIV 相关脂肪营养不良中的作用。
BioDrugs. 2011 Dec 1;25(6):405-8. doi: 10.2165/11208290-000000000-00000.

引用本文的文献

1
[Application of hairpin shaped incision combined with cover-lifting flap in plastic surgery of huge fat pad on nape and back].[发夹形切口联合掀盖皮瓣在项背部巨大脂肪垫整形术中的应用]
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2023 Sep 15;37(9):1133-1137. doi: 10.7507/1002-1892.202305016.

本文引用的文献

1
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.抗病毒治疗转换后病毒抑制人群的体重变化：来自随机临床试验的汇总数据。
Clin Infect Dis. 2021 Oct 20;73(8):1440-1451. doi: 10.1093/cid/ciab444.
2
Tesamorelin improves fat quality independent of changes in fat quantity.特马瑞林可改善脂肪质量，而不依赖于脂肪量的变化。
AIDS. 2021 Jul 15;35(9):1395-1402. doi: 10.1097/QAD.0000000000002897.
3
HIV and antiretroviral therapy-related fat alterations.HIV 和抗逆转录病毒治疗相关的脂肪改变。
Nat Rev Dis Primers. 2020 Jun 18;6(1):48. doi: 10.1038/s41572-020-0181-1.
4
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.抗逆转录病毒治疗起始后体重增加：随机对照临床试验中的危险因素。
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389. doi: 10.1093/cid/ciz999.
5
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.多替拉韦加利伟酯联合两种不同的替诺福韦前药治疗 HIV。
N Engl J Med. 2019 Aug 29;381(9):803-815. doi: 10.1056/NEJMoa1902824. Epub 2019 Jul 24.
6
Lower serum adiponectin level is associated with lipodystrophy among HIV-infected men in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN) study.血清脂联素水平降低与接受有效治疗时代的 HIV 感染男性（Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy，SUN）研究中的脂肪营养不良有关。
HIV Med. 2019 Sep;20(8):534-541. doi: 10.1111/hiv.12754. Epub 2019 May 31.
7
Long-term body composition changes in antiretroviral-treated HIV-infected individuals.接受抗逆转录病毒治疗的HIV感染者的长期身体成分变化。
AIDS. 2016 Nov 28;30(18):2805-2813. doi: 10.1097/QAD.0000000000001248.
8
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.拉替拉韦或蛋白酶抑制剂起始治疗后的身体成分变化：ACTG A5260s研究
Clin Infect Dis. 2016 Apr 1;62(7):853-62. doi: 10.1093/cid/ciw017. Epub 2016 Jan 20.
9
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.感染HIV且腹部脂肪过多患者对生长激素释放因子类似物替莫瑞林治疗反应的预测因素
PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. eCollection 2015.
10
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.接受特立帕肽治疗的 HIV 感染患者内脏脂肪减少与代谢特征改善相关。
Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10.

替莫瑞林对伴有和不伴有颈背脂肪的HIV感染者的影响：III期双盲安慰剂对照试验的事后分析

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.

作者信息

Rahman Farah, McLaughlin Taryn, Mesquita Pedro, Morin Josee, Potvin Diane, De Chantal Marilyn, Aberg Judith A

机构信息

Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Theratechnologies Inc., Montréal, Canada.

出版信息

J Clin Transl Sci. 2022 Dec 7;7(1):e40. doi: 10.1017/cts.2022.515. eCollection 2023.

DOI:10.1017/cts.2022.515
PMID:36845310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9947601/
Abstract

Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response. Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT = 0.657, WC = 0.093). These data demonstrate that tesamorelin is equally effective and should be considered in the treatment of excess VAT regardless of the presence of dorsocervical fat.

摘要

替沙莫瑞林是一种合成的生长激素释放激素，适用于减少感染HIV人群的内脏脂肪组织（VAT）。在此，我们对一项III期临床试验中接受替沙莫瑞林治疗26周的参与者进行了事后分析。根据替沙莫瑞林反应进行分层，比较了有和没有颈背脂肪的个体之间的疗效数据。在替沙莫瑞林反应者中，两个颈背脂肪组的VAT和腰围（WC）均下降，且无统计学差异（VAT = 0.657，WC = 0.093）。这些数据表明，无论是否存在颈背脂肪，替沙莫瑞林在治疗过多的VAT方面同样有效，均应予以考虑。